Statement from the CEO

Kancera has laid the foundation for new drugs against cancer and inflammation through medical discoveries, product development and clinical safety studies. Commercialization of the company's patent-pending assets takes place through partnerships with pharmaceutical companies following positive results from patient studies.

Thomas Olin, CEO Kancera

Continued strong recruitment of patients to the FRACTAL trial in cardiac patients being conducted in England. Decisions regarding the clinical cancer study will be made during September.

The FRACTAL study in myocardial infarction patients is developing according to plan

 In the fourth quarter of 2021, Kancera initiated the phase IIa clinical study FRACTAL, which aims to document the safety and cardioprotective effect (with biomarkers) of the Fractalkine blocker KAND567 in patients who have suffered an infarction in the anterior wall of the heart chamber. The study is run in collaboration with the NHS Foundation at the two prominent university hospitals Freeman Hospital and James Cook Hospital in Great Britain.

The FRACTAL study has so far enrolled 45 patients, which is gratifying and that progress is being made according to plan to include all 60 of the study’s patients during the year.

Cardiovascular diseases are the most common cause of premature death in the world today, and of these, heart attacks dominate. Annually, approximately 500,000 individuals suffer from a large heart attack in the US and Europe, and approximately 25% of those affected develop a serious complication or die within five years. The need for adequate and effective treatments is therefore extensive.

Strong alternatives for continued value building within the Fractalkine project

Kancera’s preclinical research has shown that Fractalkine blockers have the potential to address significant medical needs in both cancer and acute inflammation (in the heart and kidney). During the summer, Kancera completed a series of research studies that provide support that the company’s Fractalkine blockers have a slowing effect in preclinical models of ovarian cancer. The question that remains to be investigated is how these results can be translated into clinical reality. That analysis is ongoing in collaboration with gynecological oncology expertise and will provide the basis for a decision during the month of September if Kancera chooses to apply for permission for a first clinical study with KAND567 against recurrent ovarian cancer. In parallel with this analysis, Kancera and the Nordic expert network against gynecological cancer (NSGO) have signed a letter of intent with the aim of preparing a possible study in collaboration with large university hospitals and leading cancer researchers in Sweden, Denmark and Norway.

All in all, during the autumn we look forward to a continued strong development of the FRACTAL study in heart patients and a decision on direction for continued value building within the Fractalkine project.

Solna, August 19th, 2022
Thomas Olin
CEO Kancera AB (publ)